Eduard Jirkovsky, PharmD., PhD.

Born: February 21, 1984, Tabor, Czech Republic.

Education, Academic and Scientific Degrees

  • 2015 – PharmD. (Fac. Pharmacy, Charles Univ.), 2013 – PhD. in Medical Pharmacology (Fac. Medicine in Hradec Kralove, Charles Univ.), 2008 – MSc. in Pharmacy (Fac. Medicine in Hradec Kralove, Charles Univ.)

Working Experience

  • 2017 – Assistant professor (Dep. Pharmacology, Fac. Pharmacy, Charles Univ.)
  • 2014-2017 – Assistant professor, 2012 – Lecturer, 2008 – Research assistant (all appointments are at Dep. Pharmacology, Fac. Medicine in Hradec Kralove, Charles Univ.)

International Experience

  • 2019 (Feb-Sep) - Dr. Gavin Richardson's Lab - Cardiovascular Research Centre, Institute for Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

Research Interests

  • Cardiotoxicity of antineoplastic agents, pharmacological cardioprotection

Teaching

  • Since 2008 – teaching of seminars and practical classes of Pharmacology I and II in study programme General Medicine (since 2013 also in study programme Dentistry, since 2015 also in English), since 2015 – teaching of lectures of Pharmacology I and II in study programme of General Medicine and Dentistry (Fac. Medicine in Hradec Kralove, Charles Univ.)
  • Since 2017 - teaching of seminars of Pharmacology I and II in study programme Pharmacy (Fac. Pharmacy, Charles Univ.)

Memberships in Scientific Societies

  • Member of European Section of International Society for Heart Research (ISHR)
  • Member of Czech Society for Experimental and Clinical Pharmacology and Toxicology

Awards

  • 2015 – EPHAR Poster Award of 65th Pharmacology days; 2013 – Best publication of the year 2012 of young authors (in experimental pharmacology); 2010 – Best Poster Award of 60th Pharmacology days (all awards of the Czech Society for Clinical and Experimental Pharmacology and Toxicology)
  • 2011 – Best Lecture Award (2nd place) at 7th Postgraduate Medical Students Conference (Hradec Kralove)

Peer Review

  • Reviewer of manuscripts submitted into scientific journals with IF (>5)
  • Reviewer of grant applications: Czech (GA UK)
  • Master´s thesis (FAF UK)

Grant Projects

  • Principal investigator: GA UK (1x)
  • As a co-investigator (10x): GA CR (3x), Progres (1x), PRVOUK P37 (1x), VZ MSM (1x), IGA MZ (1x), GA UK (1x), SVV LFHK (4x).

Publications and Citations (in total):

– Number of publications with IF in WoS/Scopus: 15/15

– Number of citations in WoS/Scopus – total 432/409, without self-citations 402/377.

– H-index in WoS/Scopus (with self-citations) = 9/9.

– ORCID: 0000-0003-4286-4811; Scopus ID: 36627424600; Researcher ID: A-7297-2017.

Summary of all publications:

  1. Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, Brazdova P, Kubes J, Sotakova-Kasparova D, Mazurova Y, Adamcova M, Vostatkova L, Holzerova K, Kolar F, Simunek T, Sterba M. In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. Clin Sci (Lond). 2019;133(16):1827-1844. (IF = 5,237) (Q1)
  2. Jirkovsky E, Jirkovska A, Bures J, Chladek J, Lencova O, Stariat J, Pokorna Z, Karabanovich G, Roh J, Brazdova P, Simunek T, Kovarikova P, Sterba M. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. Journal of Pharmacology and Experimental Therapeutics. 2018 Mar;364(3):433-446. (IF = 3.876) (Q1)
  3. Lencova-Popelova O, Jansova H, Jirkovsky E, Bures J, Jirkovska-Vavrova A, Mazurova Y, Reimerova P, Vostatkova L, Adamcova M, Hrochf M, Pokorna Z, Kovarikova P, Simunek T and Serba M. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? Toxicology. 2016;372:52-63. (IF=3.582) (Q1)
  4. Adamcova M, Popelova-Lencova O, Jirkovsky E, Simko F, Gersl V and Sterba M. Cardiac troponins - Translational biomarkers in cardiology: Theory and practice of cardiac troponin high-sensitivity assays. Biofactors. 2016;42:133-148. (IF=3.236)
  5. Lencova-Popelova O, Jirkovsky E, Jansova H, Jirkovska-Vavrova A, Vostatkova-Tichotova L, Mazurova Y, Adamcova M, Chladek J, Hroch M, Pokorna Z, Gersl V, Simunek T and Sterba M. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Journal of Molecular and Cellular Cardiology. 2016;91:92-103. (IF=5.680) (Q1)
  6. Adamcova M, Lencova-Popelova O, Jirkovsky E, Mazurova Y, Palicka V, Simko F, Gersl V and Sterba M. Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. International Journal of Cardiology. 2015;201:358-367. (IF=4.638) (Q1)
  7. Jirkovska-Vavrova A, Roh J, Lencova-Popelova O, Jirkovsky E, Hruskova K, Potuckova-Mackova E, Jansova H, Haskova P, Martinkova P, Eisner T, Kratochvil M, Sus J, Machacek M, Vostatkova-Tichotova L, Gersl V, Kalinowski D, Muller M, Richardson D, Vavrova K, Sterba M and Simunek T. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research. 2015;4:1098-1114. (IF=2.161)
  8. Lencova-Popelova O, Jirkovsky E, Mazurova Y, Lenco J, Adamcova M, Simunek T, Gersl V and Sterba M. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One. 2014;9:e96055. (IF=3.234) (Q1)
  9. Jirkovsky E, Lencova-Popelova O, Hroch M, Adamcova M, Mazurova Y, Vavrova J, Micuda S, Simunek T, Gersl V and Sterba M. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology. 2013;311:191-204. (IF=3.745) (Q1)
  10. Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V and Simunek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxidants & redox signaling. 2013;18:899-929. (IF=7.667) (Q1)
  11. Jirkovsky E, Popelova O, Krivakova-Stankova P, Vavrova A, Hroch M, Haskova P, Brcakova-Dolezelova E, Micuda S, Adamcova M, Simunek T, Cervinkova Z, Gersl V and Sterba M. Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. Journal of Pharmacology and Experimental Therapeutics. 2012;343:468-478. (IF=3.891) (Q1)
  12. Vavrova A, Popelova O, Sterba M, Jirkovsky E, Haskova P, Mertlikova-Kaiserova H, Gersl V and Simunek T. In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Archives of Toxicology. 2011;85:525-535. (IF=4.674) (Q1)
  13. Sterba M, Popelova O, Lenco J, Fucikova A, Brcakova E, Mazurova Y, Jirkovsky E, Simunek T, Adamcova M, Micuda S, Stulik J and Gersl V. Proteomic insights into chronic anthracycline cardiotoxicity. Journal of Molecular and Cellular Cardiology. 2011;50:849-862. (IF=5.166) (Q1)
  14. Nachtigal P, Sterba M, Popelova O, Vecerova L, Kudlackova Z, Jirkovsky E and Gersl V. Daunorubicin does not induce immunohistochemically detectable endothelial dysfunction in rabbit aorta and femoral artery. Histology and Histopathology. 2011;26:551-562. (IF=2.480)
  15. Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR and Simunek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol. 2010;23:1105-14. (IF=4.148) (Q1)

© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico